Appeal No. 2000-0599
Application No. 08/357,363
60. 9-(4-hydroxy-3-hydroxymethylbut-1-yl) guanine, in crystalline form, having a
purity of greater than 95% by weight.
61. A pharmaceutically acceptable salt of 9-(4-hydroxy-3-hydroxymethylbut-1-yl)
guanine.
The examiner relies on the following references:
Huber 3,624,251 Nov. 30, 1971
Slater et al. (Slater) 3,688,438 Sep. 5, 1972
Walker et al. (Walker) 3,706,181 Dec. 19, 1972
Niebylski et al. (Nieblyski) 3,790,365 Feb. 5, 1974
Verheyden et al. (Verheyden) 4,507,305 Mar. 26, 1985
Thomas et al. (Thomas) 4,565,867 Jan. 21, 1986
Knudsen 4,689,129 Aug. 25, 1987
Bell et al. (Bell) 4,714,787 Dec. 22, 1987
Hannah et al. (Hannah) 4,845,084 July 4, 1989
Ellis 4,910,035 Mar. 20, 1990
Eisner et al. (Eisner) 5,185,365 Feb. 9, 1993
Chou 5,401,861 Mar. 28, 1995
Grose, W.F.A., English Language Translation of Doctoral Thesis (1971)
Pandit et al. (Pandit), AA New Class of Nucleoside Analogues. Synthesis of N1 -
pyrimidinyl- and N9 -purinyl-4'-hydroxy-3-(hydroxymethyl)butanes,@ Synthetic
Communications, Vol. 2, No. 6, pp. 345-351 (1972)
Greene, in Protective Groups in Organic Synthesis, John Wiley & Sons, New York, pp.
29-31 (1981)
Stewart, in The Peptides, Vol.3, Academic Press, New York, pp. 180-181 (1981)
The claims stand rejected as follows:
I. Claims 32, 33, 45 and 46 under the second paragraph of 35 U.S.C. ' 112.
II. Claims 33, 59, 60 and 61 under the first paragraph of 35 U.S.C. ' 112 as
lacking an adequate written description in the specification.
III. Claims 32, 33 and 45 under 35 U.S.C. ' 102(b) as anticipated by Pandit.
3
Page: Previous 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Next
Last modified: November 3, 2007